Market research
HPHA.F Heidelberg Pharma AG
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 118M
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- 0.77
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- DE000A11QVV0
- Market cap
- 118M
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- 0.77
About
About Heidelberg Pharma AG
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the treatment of non-Hodgkin lymphoma; HDP-103, a proprietary ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-201 for the treatment of colorectal cancer; and TAK-ATAC for the treatment of oncology. In addition, the company develops TLX250-CDx, a diagnostic antibody for kidney cancer that is in Phase III trials, as well as for the treatment of bladder cancer. Further, it develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for the treatment of kidney cancer; and RHB-107, an orally serine protease inhibitor that is in Phase II study to treat COVID-19. The company has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is headquartered in Ladenburg, Germany.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HPHA.F discussion.
5 years, 4 months ago
Heidelberg Pharma AG is currently in a long term uptrend where the price is trading 16.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.1.
Heidelberg Pharma AG's total revenue sank by 11.4% to $1M since the same quarter in the previous year.
Its net income has dropped by 31.1% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 59.3% to $-4M since the same quarter in the previous year.
Based on the above factors, Heidelberg Pharma AG gets an overall score of 2/5.